To disseminate information and provide leadership related to health economics and outcomes research of precision medicine and advanced therapies.


  • Establish a forum for members to engage in discussion related to the challenges of translating precision medicine and advanced therapies into clinical practice.
  • Promote education related to the health economics of precision medicine and advanced therapies.
  • Investigate the demonstration of value and the use of innovative payment models for precision medicine, cell therapies, gene therapies, and tissue-engineered products

ISPOR - Precision Medicine and Advanced Therapies

The term "precision medicine" is often described as providing "the right patient with the right drug at the right dose at the right time.” More broadly, precision medicine (also known as personalized medicine) may be thought of as the tailoring of a medical treatment to the individual’s characteristics, needs, and preferences during all stages of care, including prevention, diagnosis, treatment, and follow-up. Advance therapies (also known as regenerative medicine), which include cell therapies, gene therapies, and tissue-engineered products are used in the precision medicine approach to care. These advanced therapies are often one-time treatments that are potentially curative. Together, precision medicine and advanced therapies reflect some of the most cutting-edge medical technologies available, but these therapies have unique considerations and are very different than traditional medications. The Precision Medicine and Advanced Therapies Special Interest Group seeks to explore issues related to the approval, payment, utilization, and evidence development related to the use of these technologies so they can be better used to improve the population’s health.



Renske ten Ham, PharmD

Assistant Professor, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht
Amsterdam, NH, Netherlands


Melanie Whittington, MS, PhD

Director of Health Economics, Institute for Clinical and Economic Review (ICER)
Boston, MA, United States

Past Chair

Molly Purser, MBA, BS, PhD

Assoc Director, VEO, Oncology, Cell & Gene Therapy, GSK
Apex, NC, United States

Working Groups:

Member Engagement:

These activities allow for a variety of members to participate and also facilitates disseminating content.


Aditi Aggarwal

Manager, IQVIA
Gurgaon, HR, India

Ka Keat Lim, MSc, RPh

Research Fellow, King's College London
Kuala Lumpur, 14, Malaysia

Simran Tiwana, MBA, PhD

Sr. Director US HEOR CAR-T Portfolio, BMS
GURNEE, IL, United States

Mo Yang, PhD

Director, EMD Serono Inc. - Rockland, MA
Rockland, MA, United States

Key Project

Health Technology Assessment of Next Generation Diagnostic Testing Approaches 

Joint project with the Medical Devices and Diagnostics Special Interest Group


Susan Snyder, MBA, BS, PhD

Associate Professor, Georgia State University, School of Public Health
Atlanta, GA, United States

Objectives and Rationale of the Key Project

In the past 2-3 years there has been an explosion in the availability and utilization of next generation testing (NGT) that includes multiple genes/genomic biomarkers.  A recent report indicates that between March 2017 and 2018 more than 800 new multigene panels entered a market with more than 8,500 already existing panels in the US alone.  While the compiled evidence for most NGTs is sparse to non-existent, the total amount of data being generated through routine use, and thus potentially available for evaluating their real-world clinical utility in HTA decision-making is substantial. Despite these recommendations and the increasingly prevalent use of such tests, few HTAs have been conducted and even fewer are reimbursed by payers. The challenges of defining and assessing the value of NGS testing approaches including data gaps, clinical practice issues, reimbursement/ funding considerations, and potential solutions will be addressed.

Questions or ideas? Please send an email to PrecisionMedSiG@ispor.org




Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now